HOME >> BIOLOGY >> NEWS
New research on safety of intracoronary delivery of adenovector reported in cover story of Molecular Therapy

SAN DIEGO, California December 3, 2001 Collateral Therapeutics, Inc. (Nasdaq: CLTX) announced that preclinical in vitro and in vivo results reported in the December 2001 issue of Molecular Therapy showed that male reproductive cells (germ cells) were unaffected following intracoronary delivery of Collaterals adenovector (adenovirus serotype 5 Ad5). These findings confirm other research studies in which potential risks associated with inadvertent germ line transmission following adenoviral administration have been shown to be highly unlikely.

In the study, led by Robert E. Braun, Ph.D. Associate Professor of Genetics at the University of Washington, gene expression after adenovirus delivery was analyzed from a series of both in vitro and in vivo studies. The in vitro studies demonstrated that germ cells grown in cell culture were refractory to infection by Collaterals adenovector. To assess the risk of germ line transmission in vivo, researchers used a mouse model to deliver human recombinant Ad5 carrying a germ cell-specific promoter fused to a reporter gene directly into the left ventricular cavity of the heart. They observed that the reporter gene protein was not expressed in developing spermatids or mature sperm, with analyses performed at multiple time points after administration to evaluate all major stages of germ cell development. Importantly, the in vivo studies did not detect infection of the reproductive stem cells. The positive results from these studies are consistent with other recent studies using different models and routes of delivery. However, this is the first study that directly assessed the ability of an adenovirus to result in gene expression in extremely large numbers (i.e., millions) of germ line cells, and the first to assay infection of the reproductive stem cell population.

This study provides significant new information further supporting the safety of the use of the adenovirus as a vehicle to deliver therapeut
'"/>

Contact: Lora Pike
lpike@collateralthx.com
858-794-3410
Collateral Therapeutics
1-Dec-2001


Page: 1 2 3

Related biology news :

1. Leader in cancer treatment and prevention research honored
2. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative
3. Scientists to prototype cyberinfrastructure for research and education access to ocean observatories
4. Belgian researchers explore revolutionary approach to angiogenesis
5. Award winning researchers reveal potential new role for Glivec
6. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
7. 16 APS exercise research highlights, from reduced flu mortality to proteomics & obesity
8. Gene chips research in cotton could lead to superior variety
9. Groundbreaking research could ignite new solutions to heat transfer in nano-devices
10. New hydrothermal vents discovered as South Pacific Odyssey research begins
11. University of Alberta researcher looks for clues to mysterious disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/16/2019)... (PRWEB) , ... April 16, 2019 , ... ... markets, celebrated the grand opening of its new medical device facility on Friday, ... , Located in Memphis, TN the new facility includes 108,500 square feet and ...
(Date:4/12/2019)... (PRWEB) , ... April 11, 2019 , ... ... is excited to announce their efforts to help decrease opioid abuse by offering ... no charge or a discounted rate, up to 50% off. , In 2019, ...
(Date:4/4/2019)... , ... April 02, 2019 , ... ... and development solutions for drugs, biologics and consumer health products, today announced that ... takes place at the Gaylord National Harbor Hotel, Oxon Hill, Maryland, on April ...
Breaking Biology News(10 mins):
(Date:4/8/2019)... ... April 08, 2019 , ... CallTower, ... today the launch of their app integration solution, CT Cloud Unite. CT ... applications while using CT Cloud Voice and Skype for Business solutions. This robust ...
(Date:3/29/2019)... ... March 28, 2019 , ... Specific Diagnostics announced ... proceeded with a second stage of funding for Specific’s Reveal™ rapid antibiotic susceptibility ... top of the $1.7 million already awarded by CARB-X. The additional $1.7M will ...
(Date:3/23/2019)... Pa. (PRWEB) , ... March 22, 2019 , ... ... of its LenS3 Multi-Angle Light Scattering (MALS) detector , offering a revolutionary ... of synthetic polymers, polysaccharides, proteins, and biopolymers. A novel optical design, a unique ...
(Date:3/19/2019)... ... ... webinar will review strategies for data management in modular and adaptive clinical trials. , ... up to 30 percent, reducing cost while increasing quality, achieving clinical site set-up faster , ... data – reducing risk and impact on trial success, trial teams, and trial execution , ...
Breaking Biology Technology:
Cached News: